Drug updated on 5/17/2024

Dosage FormCapsule (oral; 40 mg, 60 mg, 80 mg)
Drug ClassVesicular monoamine transporter 2 inhibitors
Ongoing and
Completed Studies


  • For the treatment of adults with tardive dyskinesia.
  • For the treatment of chorea associated with Huntington’s disease.

Latest News

loading GIF

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Valbenazine (Ingrezza) is indicated for the treatment of adults with tardive dyskinesia and chorea associated with Huntington’s disease. It has been shown to be more effective than placebo in inducing a 'slight improvement' in psychosis symptoms without a significant difference from active comparators.
  • Four systematic reviews/meta-analyses focused on the efficacy, safety, and subpopulation considerations of valbenazine as well as deutetrabenazine.
  • Compared to traditional antipsychotics that induce dopamine receptor supersensitivity resulting in tardive dyskinesia, valbenazine may have antipsychotic activity with a potential reduced risk of this condition.
  • Both valbenazine and deutetrabenazine demonstrated effectiveness in reducing tardive dyskinesia symptoms across various populations including an Asian cohort, suggesting their global applicability.
  • These drugs exhibit favorable safety profiles characterized by low rates of serious adverse events such as QT prolongation, parkinsonism, suicidal ideation, or mortality, which underlines their tolerability, making them promising treatment options for tardive dyskinesia.
  • Long-term studies indicate robust efficacy for valbenazine, making it a valuable option, while there is a need for more information on the long-term impact of deutetrabenazine.

Product Monograph / Prescribing Information

Document TitleYearSource
Ingrezza (valbenazine) Prescribing Information.2023Neurocrine Biosciences, Inc., San Diego, CA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines